Project/Area Number |
10558143
|
Research Category |
Grant-in-Aid for Scientific Research (B).
|
Allocation Type | Single-year Grants |
Section | 展開研究 |
Research Field |
Biomedical engineering/Biological material science
|
Research Institution | National Cardiovascular Center Research Institute |
Principal Investigator |
NAKAYAMA Yasuhide Dept. of Bioengineering, National Cardiovascular Center Research Institute, Group Head, 生体工学部, 室長 (50250262)
|
Co-Investigator(Kenkyū-buntansha) |
UEDA Hatsue Dept. of Pathology, National Cardiovascular Center Research Institute, Group Head, 病理部, 医長
NAKAYAMA Atsuyoshi Osaka National institute, Dept. of Organic Materials, Researcher, 有機機能材料部, 研究員
OYA Shoji Dept. of Bioengineering, National Cardiovascular Center Research Institute, Researcher, 生体工学部, 室員 (80311447)
NISHI Shogo Kitano Hospital, Dept of Neurosurgery, Vice Department Head, 脳外科, 副部長 (30312226)
|
Project Period (FY) |
1998 – 2000
|
Keywords | photoreaction / percutaneous treatment / stent / adhesive glue / Embolic material / Surface Design / Cardiovascular Disease / Drug Delivery |
Research Abstract |
The development of the devices and techniques for percutaneous treatment as a low invasion therapy in cardiovascular field are important especially in societies with many elderly people. Among them we have developed are as follows ; 1) visible light-induced tissue adhesive glue where styrenated gelatin and/or albumin-containing aqueous solutions with camphorquinone were gelated upon a few minutes of visible light irradiation, 2) embolic material for cerebral arteriovenous malformations and for local delivery of cytokines, 3) a novel high functional covered stent with micropore and drug delivery performance and hydrogel-coated stents both for prevention of restenosis and additionally a gene delivery device, and 4) the high performance balloon catheters with three functions of dilation of blood vessels, blood circulation and local delivery of drugs, all of which were driven by photochemistry. In addition, our efforts are also directed to application of gene therapy devices. We are pioneers in the development of these technologies and these techniques that will become the central in treatment of cardiovascular diseases.
|